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Abstract
We report the case of a two patients who presented with a solitary, asymptomatic,
angiomatoid nodule on the right thigh. Histopathological finding showed a poorly
circumscribed lesion, located in the dermis. The morphological aspect strongly
suggested the diagnosis of atypical fibrous histiocytoma (AFH), but surprisingly,
the neoplastic cells were diffusely CD30+, with a membrane staining devoid of
paranuclear dot. The lesions were tested for p80/ALK1 expression. Surprisingly,
we found a diffuse cytoplasmic positivity. Interestingly, using break-apart
fluorescent in situ hybridization (FISH), we evidenced an ALK rearrangement
in nearly 50% of the neoplastic cells. The expression of CD30 and ALK1 with
ALK gene rearrangement raised the possibility of three diagnoses: a primary
cutaneous anaplastic large cell lymphoma (ALCL), a cutaneous inflammatory
myofibroblastic tumor (IMT), an AFH of the skin associated with ALK gene
rearrangement and CD30 positivity. The three hypotheses were disc...
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of the skin with CD30 and p80/ALK1
positivity and ALK gene
rearrangement
We report the case of a two patients who presented with a solitary,
asymptomatic, angiomatoid nodule on the right thigh.
Histopathological finding showed a poorly circumscribed lesion,
located in the dermis. The morphological aspect strongly
suggested the diagnosis of atypical fibrous histiocytoma (AFH),
but surprisingly, the neoplastic cells were diffusely CD30+, with a
membrane staining devoid of paranuclear dot. The lesions were
tested for p80/ALK1 expression. Surprisingly, we found a diffuse
cytoplasmic positivity. Interestingly, using break-apart fluorescent
in situ hybridization (FISH), we evidenced an ALK rearrangement
in nearly 50% of the neoplastic cells. The expression of CD30 and
ALK1 with ALK gene rearrangement raised the possibility of three
diagnoses: a primary cutaneous anaplastic large cell lymphoma
(ALCL), a cutaneous inflammatory myofibroblastic tumor (IMT),
an AFH of the skin associated with ALK gene rearrangement and
CD30 positivity. The three hypotheses were discussed and finally,
although p80/ALK1 expression and cytogenetic abnormalities in
fibrous histiocytoma (FH) are not yet reported to the best of our
knowledge, we favored the diagnosis of AFH.
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Fibrous histiocytoma (FH) is a dermal tumor
characterized histopathologically by a prolifera-
tion of mononuclear, spindle-shaped or histio-
cytoid cells and/or multinucleated cells, often
admixed with inflammatory cells. Over the years
several clinicopathologic variants of FH have
been delineated including cellular, aneurysmal,
epithelioid, [atypical fibrous histiocytoma
(AFH); ‘pseudosarcomatous,’ dermatofibroma
with monster cells], lipidized ‘ankle-type,’ pal-
isading, cholesterotic and FH with osteoclast-like
giant cells.
AFH is a rare lesion that is similar to FH
most commonly presents on the extremities
of young to middle-aged adults as a solitary,






Fig. 1. A) Low power view reflects the observed morphological features, namely an intradermal lesion with normal epidermis. The
is the presence of variably prominent pleomorphic, spindle (fibroblast-like), oval to round and/or polyhedral (histiocytic-like) cells
with small to prominent nucleoli and abundant eosinophilic cytoplasm. B) Medium power demonstrates an intradermal tumor with
normal overlying epidermis and underlying polyhedral cells. C) A high power view reveals the cytomorphology of atypical cells. D)
Using immunohistochemistry, the tumor cells expressed CD30. E) Using immunohistochemistry, the tumor cells are also positive
for p80/ALK1. F) FISH results using the Vysis LSI Dual Color Break Apart FISH Probe that consists of a mixture of an orange
fluorochrome directed labelled 3′-ALK probe that hybridizes telomerically of the breakpoint and a green fluorochrome directed
labelled 5′-ALK probe that hybridizes centromerically of the breakpoint. Note the coexistence of the fused (yellow) and slitting (red
and green) hybridization signals in the nuclei of the tumour cells (red ellipse), consistent with an ALK gene rearrangement.
tumor is usually a dermal lesion with pleomor-
phic spindled (fibroblast-like) and polyhedral
(histiocyte-like) cells admixed with multinucle-
ate giant cells, set in a background of classic
FH. Immunohistochemical analysis may not be
essential for diagnosis but helps rule out other
possibilities in the differential diagnosis. When
completed, it typically shows focal positivity for
smooth muscle actin in the spindle cell compo-
nent whereas CD68 and CD163 may be focally
positive usually in the multinucleated cells. The
diagnosis of AFH is histomorphological and lit-
tle is known about its cytogenetic abnormalities.
Herein, we report the two first cases of AFH with
a positive expression of p80/ALK1 protein and
a rearrangement involving ALK gene showed by
fluorescent in situ hybridization (FISH).
Patient histories
Patient 1 was a 32-year-old man who presented
with a solitary, asymptomatic, angiomatoid nod-
ule on the right thigh. He had no previous
medical history. Histopathologic assessment
showed a poorly circumscribed lesion, localized
in the dermis, without extension to the subcutis.
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There was no epidermal alteration. The tumor
was composed of a proliferation of large epithe-
lioid cells with abundant eosinophilic cytoplasm.
Some were stellate and other showed a histiocy-
toid appearance (Fig. 1A,B). They were few
multinucleated cells and some resembled
anaplastic, showing hyperchromatic multi-
lobulated nuclei. The cells had vesicular nuclei
and small to prominent nucleoli. They were
admixed with spindle cells, showing fibrob-
last/myofibroblast morphology and few lympho-
cytes and histiocytes. There was a relatively low
mitotic index [3mitoses per 10 high power fields
(hpf)]. Tumor stroma was fibrous with numer-
ous dilated capillaries. These histomorphologic
aspects strongly suggested the diagnosis of AFH.
Because few anaplastic cells were recognized, a
phenotypic study was performed using immuno-
histochemistry. As expected, the neoplastic
cells expressed CD10 and D2-40. Surprisingly,
tumor cells were also diffusely CD30 positive
with a membrane staining devoid of paranu-
clear dots (Fig. 1C). CD45, CD2, CD3, CD5,
CD7, CD4, CD8, CD20, CD79a, CD138, PAX5,
S100, MelanA, smooth muscle actin and desmin
were all negative. CD168 and CD63 staining
highlighted stromal histiocytes. Because of the
fibroblast–myofibroblast-like component and
the strong positivity for CD30, the lesion was
tested for p80/ALK1 expression (Fig. 1D).
Surprisingly, we found a diffuse cytoplasmic
positivity. B and T-cell clonality studies per-
formed after DNA extraction from the paraffin
blocks showed a polyclonal aspect. Interestingly,
using break-apart FISH, we showed an ALK
rearrangement in nearly 50% of the neoplastic
cells (Fig. 1C). The diagnosis of AFH with ALK
gene rearrangement was rendered.
Patient 2 was a 23-year-old woman who pre-
sented with an 18-month history of an unique
pinkish 7mm-nodule of the right leg. The
clinician initially suspected a Spitz nevus
or a clear cell acanthoma. Local excision
was performed. Microscopically, the tumor
was characterized by a dermis nodular fairly
well-circumscribed proliferation of large epithe-
lioid and moderately-atypical cells with scattered
lymphocytes and multinucleate cells in the back-
ground. The tumor cells often had irregular
nuclei, pre-eminent nucleoli and abundant
cytoplasm. In immunohistochemical staining,
the atypical cells were positive for CD68, CD163,
CD4 and CD30. S100, HMB45, Melan-A, CD2,
CD3, CD5, p63, pancytokeratin, CD31, CD34
and smooth muscle actin were all negative.
The lesion was tested for p80/ALK1 expression
and showed diffuse cytoplasmic positivity. FISH
analysis showed a rearrangement involving ALK .
The diagnosis of histiocytoma with atypical cells
and ALK rearrangement was made.
Materials and methods
The histopathologic diagnosis of AFH was made
on hematoxylin/eosin/safranin-stained sections
and periodic acid-Schiff-stained sections.
Immunohistochemistry was carried out using
an indirect immunoperoxidase method on
formalin-fixed paraffin-embedded (FFPE) tis-
sues. The following markers were used after
appropriate antigen retrieval: CD20 (clone
L26, Dako, Denmark A/S 1 : 500), CD79a
(clone JCB117, Dako, Denmark A/S 1 : 20),
Pax5 (clone SP34, Ventana Roche Diagnos-
tics, Mannhein, Germany), CD138 (clone
MI15, Dako, Denmark A/S 1 : 100), CD2
(clone MRQ-11, Ventana Roche Diagnostics,
Mannhein, Germany), CD3 (clone F7238, Dako,
Denmark A/S 1 : 20) CD5 (clone 4C7, Leica
Microsystem, 1 Newcastle upon Tyne, United
Kingdom : 100) CD7 (clone CBC-37, Dako,
Denmark A/S 1 : 25), CD4 (clone SP35, Ven-
tana Roche Diagnostics, Mannhein, Germany),
CD8 (clone C8/144B, Dako, Denmark A/S 1 :
25), CD10 (clone SP67, Ventana Roche Diag-
nostics, Mannhein, Germany), CD30 (clone
Ber-H2, Ventana Roche Diagnostics, Mannhein,
Germany), CD163 (clone MRQ-26, Ventana
Roche Diagnostics, Mannhein, Germany) CD68
(clone KP1, Dako, Denmark A/S 1 : 500), ker-
atin AE1/AE3 (clone AE1/AE3, Dako, Denmark
A/S 1 : 100), P63 (clone 4A4, Ventana Roche
Diagnostics, Mannhein, Germany), CD31 (clone
JC70A, Dako, Denmark A/S 1 : 20), CD34 (clone
QBEND/10, Beckman-Coulter IMMUNOTECH
SAS, Marseille, France) ALK (clone ALK1,
Dako, Denmark A/S 1 : 50), smooth muscle
actin (clone 1A4, Dako, Denmark A/S 1/200),
desmin (clone D33, Dako, Denmark A/S 1 :
150), D240 (clone D240, Eurogentec, Dublin
Ohio, USA 1 : 50), PS100 (polyclonal anti-S100,
Dako, Denmark A/S 1 : 3200) , HMB45 (clone
HMB45, Dako, Denmark A/S 1 : 100), MelanA
(clone A103, Dako, Denmark A/S 1 : 25), KI67
(clone MIB-1, Dako, Denmark A/S 1 : 100).
Fluorescence in situ hybridization (FISH)
analysis was performed on 3 μm tissue sections
(whole sections) using the Vysis LSI ALK Break
Apart Rearrangement Probe (Vysis/Abbott
Molecular Diagnostics, Wiesbaden-Delkenheim,
Germany) according to the manufacturer’s
recommendations. Slides were analyzed with
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a Zeiss AxioImager Z1 fluorescence micro-
scope (Labexchange, Burladingen, Germany)
equipped with microscope-specific filters and
double filter (XF53, Omega Optical, Brat-
tleboro, VT, USA) suitable for the fluorescein
isothiocyanate, SpectrumOrange and Texas Red
labelled probes. Slides were analyzed indepen-
dently by three scorers (Maryse Baia, Christiane
Copie-Bergman, Vanessa Szablewski) with a
×100 oil immersion objective. For archiving,
images were captured with ×40 objective using
a Hamamatsu digital camera attached to the
fluorescence microscope (Hamamatsu Photon-
ics France SARL, Massy, France) and visilog
6.9 software (FEI, Les Ulis, France). Cases were
considered positive when more than 20% of
cells displayed split signals.
The detection of clonally rearranged
immunoglobulin (Ig) and T-cell receptor (TCR)
genes was performed using BIOMED-2 primer
sets (Eurofins MWG Operon, Ebesberg, Ger-
many) and conditions. DNA was extracted from
non-microdissected FFPE tissue sections. In each
case, polymerase chain reaction (PCR) ampli-
fication was carried out in duplicate. The PCR
products of Ig/TCR genes were analyzed for
clonality assessment by GeneScanning (Eurofins
GeneScan, Metairie, Louisiana, USA).
Discussion
FH is the most common mesenchymal neoplasm
of the skin. To date, the precise line of differ-
entiation is uncertain. Clinically, most lesions
present as a solitary red or brown nodules on
the extremities of young to middle-aged adults.
Microscopic features usually show an ill-defined
dermal tumor characterized by a proliferation
of mononuclear histiocytoid and stellate or
spindle-shaped cells admixed with few multinu-
cleated and inflammatory cells. Several clinico-
pathologic variants of FH have been delineated.
AFH is a rare variant of cutaneous FH also
called pseudosarcomatous fibrous histiocytoma or
dermatofibroma with monster cells. It was first
described in 1983.1 This tumor is seen as a
solitary firm cutaneous nodule in a broad age
range (5–79 years; median: 38 years). Anatomic
distribution is wide with most cases occurring in
the lower and upper extremities (79%).2 Lesion
size ranges from 0.4 to 8 cm (median 1.5 cm).
AFH usually presents as a dermal lesion with
pleomorphic atypical cells set in a background
of typical FH. The pleomorphic cells are spin-
dled, oval to round and/or polyhedral. The
pleomorphic cells have large, irregular (round
to oval, cigar-shaped or bizarre), sometimes
hyperchromatic, nuclei with small to promi-
nent nucleoli and often abundant eosinophilic
cytoplasm.2 Variably prominent multinucle-
ate giant cells, commonly exhibiting foamy or
hemosiderin-rich cytoplasm, may be present.
Mitotic figures may range from 1 to 15/10hpf.
There is a spectrum from lesions showing only
focal mild pleomorphism to those exhibiting
marked pleomorphism. Superficial involvement
of the subcutis is seen in one third of the cases.
Immunohistochemically, the tumor cells are pos-
itive for vimentin and negative for S100 protein,
epithelial membrane antigen, cytokeratin and
HMB45. Alpha smooth muscle actin, desmin
and CD34 are sometimes focally positive. CD68
and CD163 may be focally positive, usually in
multinucleated cells.3 The spindle cells can
show focal positivity for smooth muscle actin
and usually express D2-40.4 Positivity for CD68
and factor XIIIa are variable. MiB1 is expressed
in less than 10% of the cells.
Histopathologically, AFH should be dif-
ferentiated from a number of benign and
malignant cutaneous tumors with pleomorphic
and/or anaplastic cytomorphology including
melanoma, spindle cell squamous cell carci-
noma or primary cutaneous anaplastic large cell
lymphoma (ALCL). In our cases, melanocytic
and epithelial lesions were ruled out because of
the negativity for corresponding markers.
The expression of CD30 and ALK1 with ALK
gene rearrangement raised the possibility of
a primary cutaneous anaplastic large cell lym-
phoma (ALCL). Patient 2 was first misdiagnosed
as ALCL, but after hematologic evaluation and
expert histopathologic evaluation, this diagno-
sis was revised. For patient 1, the possibility of
ALCL was ruled out because of the histopatho-
logic findings, the lack of expression of all
leukocyte and T-cell markers, and the absence
of a clonal rearrangement of T-cell receptor
(TCR) genes. The diagnosis of unusual fibrohistio-
cytic/fibroblastic tumor with ALK gene rearrangement
was thus proposed, allowing us to discuss an AFH
of the skin or a cutaneous inflammatory myofi-
broblastic tumor (IMT) associated with ALK
gene rearrangement and CD30 positivity.
IMT is characterized by a proliferation of
myofibroblasts set in a myxoid to collagenous
stroma with a prominent polymorphous inflam-
matory infiltrate. Although the lung is the best
known and most common site,5 IMT can occur
in many organs. Only few cases occurring in
the skin have been previously reported, so
that cutaneous IMT should be considered as
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a diagnosis of exclusion.6–8 The spindle cells
usually express vimentin and smooth muscle
actin and approximately 50% of IMT are pos-
itive for p80/ALK1. P80/ALK1 expression in
IMT reliably predicts the presence of an ALK
gene rearrangement, which can be detected by
FISH or reverse transcription-polymerase chain
reaction (RT-PCR).
Although p80/ALK1 expression and cytoge-
netic abnormalities in FH have not yet been
reported to the best of our knowledge, we favor
the diagnosis of AFH in both tumors, as this fits
with the clinical presentation, the histopatho-
logic features and the negativity for smooth
muscle markers that should be present in IMF.
Little is known about chromosomal abnormali-
ties in FH. Nevertheless the molecular genetics
of angiomatoid FH have become increasingly
understood. Angiomatoid FH was reported in
1979 by Enzinger as a variant of malignant
fibrous histiocytoma [angiomatoid malignant
fibrous histiocytoma (MFH)], which showed
a predilection for extremities and occurred at
much younger age than other subtypes of MFH.
A number of reports describe EWSR1/CREB1,
EWSR1/ATF1 and FUS/ATF1 gene fusions9,10
in this context. About 93% of angiomatoid
FH have a rearrangement of EWSR1 (as mani-
fested by the EWSR1/CREB1 and EWSR1/ATF1
fusion genes), whereas about 7% of cases have
a rearrangement of FUS. FISH for EWSR1 and
FUS is widely available and is used routinely in
medical centers that encounter large numbers
of sarcomas/mesenchymal neoplasms.
Unfortunately, the designation angiomatoid
FH is confusing, as this tumor is not a variant
of FH and has no relation with aneurysmal FH.
Angiomatoid FH has therefore been recognized
as a distinct clinicopathologic entity by theWorld
HealthOrganization (WHO) classification of the
tumors of soft tissue and has been designated a
tumor of intermediate malignancy.
Interestingly, abnormal p80/ALK1 expression
with a variety of structural chromosomal changes
have been shown to be present in a wide variety
of soft tissue tumors, especially rhabdomyosar-
coma and malignant peripheral nerve sheath
tumor (MPNST).11,12 Nevertheless, with the
exception of IMT, in all others soft tissue tumors
with abnormal p80/ALK1 expression, the corre-
sponding chromosomal abnormality was two or
multiple fused ALK signal using break-apart ALK
probe without gene rearrangement. Moreover,
MFH is one of the differential diagnoses of AFH,
and even if it could show p80/ALK1 positivity by
immunochemistry, no ALK gene rearrangement
would have been showed.
In conclusion, we report the two first diagnoses
of AFH with ALK gene rearrangement.
The exact frequency of p80/ALK1 expression
and ALK rearrangement in FH needs further
investigation.
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